| Domain | Knowledge-base statement | Evidence type/strength | Suggested ontology terms |
|---|---|---|---|
| Identity / epidemiology | Hajdu-Cheney syndrome (HCS) is an ultra-rare Mendelian connective-tissue/skeletal disorder characterized by acro-osteolysis and generalized osteoporosis; commonly cited identifiers include ORPHA:955, OMIM #102500, and MONDO:0007057 (acroosteolysis dominant type / Hajdu-Cheney syndrome groupings). Reported prevalence is **<1/1,000,000** and historical literature reviews estimate roughly **50-100 described cases**, indicating that most current knowledge comes from aggregated case reports/reviews rather than EHR-scale cohorts. (pqac-00000002, pqac-00000003, pqac-00000005, pqac-00000007, pqac-00000000) | Human clinical aggregated review evidence; moderate for definition/rarity, low for exact prevalence because of ascertainment and historical undercount. | MONDO:0007057; MeSH: use disease name if mapping required; HCS synonyms: acroosteolysis dominant type, serpentine fibula-polycystic kidney syndrome |
| Genetics / inheritance | HCS is usually **autosomal dominant** and caused by **heterozygous germline NOTCH2** pathogenic variants, typically **nonsense or small deletion/frameshift variants in exon 34**. Many cases are de novo/sporadic, but familial transmission is established. (pqac-00000002, pqac-00000003, pqac-00000005, pqac-00000015) | Human genetics + review evidence; strong for causal gene/inheritance. | HGNC:7882 **NOTCH2**; inheritance: autosomal dominant |
| Variant mechanism | Pathogenic variants truncate NOTCH2 **upstream of the PEST domain**, preserving signaling machinery but impairing NICD2 degradation, producing a **stabilized gain-of-function receptor** with excessive NOTCH2 signaling. (pqac-00000003, pqac-00000006, pqac-00000009, pqac-00000015, pqac-00000016) | Human molecular genetics + engineered mouse knock-in; strong for gain-of-function mechanism. | GO:0007219 Notch signaling pathway; protein region: PEST domain |
| Pathophysiology / mechanism | Current disease model supports **high-turnover bone loss** with increased osteoclastogenesis/bone resorption and relative dysregulation of bone formation. NOTCH2 activation is linked to pro-osteoclastogenic mediators such as **NFATC1**, **RANKL**, and **IL6**; mouse studies show osteopenia, increased osteoclast number, and increased bone resorption. (pqac-00000003, pqac-00000006, pqac-00000009, pqac-00000014, pqac-00000015) | Mechanistic review + knock-in mouse functional evidence; moderate-strong. | GO:0045453 bone resorption; GO:0030316 osteoclast differentiation; GO:0001649 osteoblast differentiation; CL:0000090 osteoclast; CL:0000062 osteoblast |
| Cardinal skeletal phenotypes | Core manifestations are **acro-osteolysis of distal phalanges**, **osteoporosis/osteopenia**, short stature, fractures, wormian bones, kyphoscoliosis, vertebral anomalies/collapse, serpentine fibula, joint laxity, and progressive distal bone resorption. These features are variable but progressive over time. (pqac-00000001, pqac-00000002, pqac-00000003, pqac-00000005, pqac-00000009) | Human case-series/review evidence; strong for recurrent phenotype set, low for precise frequency percentages. | HP:0001841 Acroosteolysis; HP:0000939 Osteoporosis; HP:0004322 Short stature; HP:0000928 Scoliosis; HP:0008466 Wormian bones |
| Craniofacial / dental / neurologic / renal / cardiovascular phenotypes | Frequent extra-appendicular features include coarse/dysmorphic facies, micrognathia, hypertelorism/telecanthus, high-arched palate, delayed/premature tooth loss, malocclusion, basilar invagination/platybasia, hydrocephalus, hearing issues, renal cysts/polcystic kidneys, congenital heart disease/patent ductus arteriosus, and recurrent respiratory infections from thoracic deformity. (pqac-00000002, pqac-00000003, pqac-00000005, pqac-00000009, pqac-00000011) | Human review + case evidence; moderate. | HP:0000347 Micrognathia; HP:0000235 Hydrocephalus; HP:0000107 Renal cyst; HP:0001643 Patent ductus arteriosus; UBERON:0002101 skull; UBERON:0001134 kidney |
| Temporal course | Onset is often **congenital or early childhood**, with early craniofacial/hand findings and later progressive skeletal fragility. The course is **chronic, age-dependent, and progressive**, with increasing disability risk from fractures, vertebral collapse, and skull-base complications. (pqac-00000001, pqac-00000003, pqac-00000004, pqac-00000009, pqac-00000011) | Human longitudinal case/review evidence; moderate. | HPO onset terms: congenital onset, childhood onset; course descriptors: progressive |
| Diagnostics | Diagnosis is primarily **clinical-radiologic plus molecular**. Imaging may show distal phalangeal acro-osteolysis, wormian bones, platybasia/basilar invagination, vertebral deformities, serpentine fibula, and renal cysts. **Genetic confirmation** is typically by sequencing **NOTCH2**, especially exon 34; broad exome/panel testing is useful when phenotype is unclear or syndromic short stature is present. (pqac-00000002, pqac-00000003, pqac-00000005, pqac-00000009, pqac-00000011) | Human clinical/review evidence; strong for gene testing utility, moderate for formal criteria. | MAXO: genetic testing; imaging terms: radiography, MRI, ultrasound; NOTCH2 single-gene testing / exome sequencing |
| Differential diagnosis | Important differentials for acro-osteolysis and overlapping syndromic features include **systemic sclerosis/scleroderma**, sarcoidosis, hyperparathyroidism, local trauma/thermal injury, neuropathic causes, progeria, and **Alagille syndrome** or other NOTCH-related disorders. (pqac-00000002, pqac-00000005, pqac-00000009) | Review evidence; moderate. | HPO anchor feature: Acroosteolysis; related disease names as differential set |
| Treatment / management | There is **no curative therapy**. Management is multidisciplinary and complication-directed: bone health surveillance, fracture prevention, orthopedic/neurosurgical management, respiratory and renal monitoring, dental care, and rehabilitation. **Bisphosphonates** are the most commonly reported pharmacologic intervention; denosumab, pamidronate, zoledronic acid, teriparatide, and romosozumab have only case-level/off-label evidence with variable benefit. (pqac-00000001, pqac-00000002, pqac-00000003, pqac-00000004, pqac-00000005, pqac-00000010) | Human case reports/reviews; low-moderate for drug efficacy, strong that no standard curative therapy exists. | MAXO: bisphosphonate therapy; denosumab therapy; physical therapy / rehabilitation; surgical management |
| Real-world implementation / safety | Real-world care issues include rehabilitation approaches (e.g., gait-focused vibrotherapy/physiotherapy), dental extraction/implant planning, and antiresorptive safety concerns such as delayed oral healing and medication-related osteonecrosis of the jaw risk in denosumab-treated patients. (pqac-00000004, pqac-00000010, pqac-00000011) | Human case evidence; low but clinically actionable. | MAXO: dental procedure management; physical therapy; supportive care |
| Prognosis | Life expectancy is not well quantified, but morbidity can be substantial due to fractures, vertebral compression/collapse, ventilatory restriction, basilar invagination, hydrocephalus, and rare sudden death/central respiratory complications. Prognosis depends on severity of skeletal and skull-base disease and adequacy of surveillance/intervention. (pqac-00000003, pqac-00000009) | Review evidence; low-moderate because no registry-scale survival data. | Prognostic features: basilar invagination, fractures, ventilatory restriction |
| Research gaps / omics | No disease-specific **single-cell**, **spatial transcriptomic**, **proteomic**, **metabolomic**, or large natural-history registry dataset was identified in the retrieved evidence; current knowledge remains dominated by case reports, reviews, and mouse models. (pqac-00000001, pqac-00000007) | Absence-of-evidence statement from available literature set; low but important for KB completeness. | Evidence gap annotation; omics not available / not established |
| Experimental models | Engineered **heterozygous Notch2 knock-in mice** recapitulate major bone features of HCS, including short femora, cortical/cancellous osteopenia, increased osteoclastogenesis and bone resorption. In a 2023 fracture-healing model, overall structural healing appeared near-normal, but callus turnover was increased and **biomechanical stability of healed femora was impaired**. (pqac-00000012, pqac-00000013, pqac-00000015, pqac-00000016) | Primary in vivo model evidence; strong for skeletal mechanism/model utility. | Mouse model; CL:0000090 osteoclast; GO:0042060 wound healing; GO:0060348 bone development |
| Other species / natural disease | No convincing naturally occurring veterinary counterpart or zoonotic relevance was identified in the retrieved evidence; current comparative biology relies mainly on engineered murine models. (pqac-00000015, pqac-00000016) | Evidence gap / comparative inference; low. | NCBI Taxon: Mus musculus (model organism) |


*Table: This table condenses the most actionable disease-characterization points for Hajdu-Cheney syndrome into a knowledge-base format, with evidence strength and ontology suggestions. It is useful for rapid curation across clinical, molecular, and translational domains.*